Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7021MR)

This product GTTS-WQ7021MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7021MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14705MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ8155MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ14253MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ10079MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ8379MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ13047MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ5068MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ7038MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Fab C225
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW